Publications by authors named "Xiao Hui Zhang"

Article Synopsis
  • Low-temperature proton exchange membrane fuel cells (PEMFCs) need very pure hydrogen gas because they are highly sensitive to carbon monoxide (CO) contamination.
  • A surface modification technique was developed, applying a 0.5-0.91 nm amorphous carbon nitride layer on PtRu/C substrates, improving hydrogen transport while blocking CO diffusion.
  • This modification significantly reduces CO adsorption, maintaining stable catalyst operation for over 20 hours even with high CO levels (1000 ppm), and allows stable performance in PEMFCs with CO concentrations up to 10 ppm, surpassing the standard limit of 0.2 ppm.
View Article and Find Full Text PDF

Objective: To evaluate the gene mutation profile and prognostic significance of adult cytogenetically normal acute myeloid leukemia (CN-AML) with mutation.

Methods: Targeted sequencing was implemented on the diagnostic bone marrow DNA samples of 141 adult CN-AML subjects with mutation. The nomogram model for leukemia-free survival (LFS) rate was generated by combining genetic abnormalities and clinical data.

View Article and Find Full Text PDF

Although acute myeloid leukemia (AML) affects hematopoietic stem cell (HSC)-supportive microenvironment, it is largely unknown whether leukemia-modified bone marrow (BM) microenvironment can be remodeled to support normal hematopoiesis after complete remission (CR). As a key element of BM microenvironment, endothelial progenitor cells (EPCs) provide a feasible way to investigate BM microenvironment remodeling. Here, we find reduced and dysfunctional BM EPCs in AML patients, characterized by impaired angiogenesis and high ROS levels, could be partially remodeled after CR and improved by N-acetyl-L-cysteine (NAC).

View Article and Find Full Text PDF

In this study, we aimed to develop nanobodies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) for cancer diagnosis and therapy. We immunized alpacas with ROR1, extracted RNA from their blood, and converted it to complementary DNA (cDNA) to amplify the VHH (variable domain of heavy-chain antibodies) sequence. This sequence was used to construct a phage library with a capacity of 8 ×10.

View Article and Find Full Text PDF

Cancer cells secrete extracellular vesicles (EV) encapsulating bioactive cargoes to facilitate inter-organ communication in vivo and are emerging as critical mediators of tumor progression and metastasis, a condition which is often accompanied by a dysregulated cholesterol metabolism. Whether EVs are involved in the control of cholesterol homeostasis during tumor metastasis is still undefined and warrant further investigation. Here, we find that breast cancer-derived exosomal miR-9-5p induces the expression of HMGCR and CH25H, two enzymes involved in cholesterol synthesis and the conversion of 25-hydroxycholesterol from cholesterol by targeting INSIG1, INSIG2 and ATF3 genes in the liver.

View Article and Find Full Text PDF

Myeloid sarcoma (MS) is a rare hematological neoplasm with poor prognosis, posing a significant clinical challenge due to the absence of effective and standardized treatments. We conducted a retrospective analysis of 162 MS patients treated at 12 centers to compare outcomes between intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our analysis revealed that allo-HSCT demonstrated superior overall survival (OS) within the initial 36 months compared to intensive chemotherapy alone (p = 0.

View Article and Find Full Text PDF
Article Synopsis
  • Chronic myelomonocytic leukemia (CMML) is a type of blood cancer where allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment, although not suitable for all patients, and relapse is a common issue.
  • A nationwide study analyzed data from 238 CMML patients who underwent allo-HSCT across 27 medical centers and 307 patients from a research database to establish a risk scoring system to predict early relapse based on certain prognostic factors.
  • Four key factors were identified that significantly increased the risk of relapse: bone marrow blasts over 10%, age greater than 60 years, low hemoglobin levels, and specific gene mutations, leading to a scoring system that categor
View Article and Find Full Text PDF
Article Synopsis
  • The study examined risk factors for measurable residual disease (MRD) positivity after allogeneic stem cell transplantation (allo-SCT) in 478 AML patients, finding that MRD positivity increased over time (4.6% at 100 days, 12.1% at 360 days, 18.3% at 3 years).
  • Positive pre-transplant MRD status and active disease before transplant were significant risk factors for MRD positivity at both 360 days and 3 years, while European LeukemiaNet (ELN) risk stratification also played a role.
  • A scoring system was developed based on these factors, showing higher scores were linked to increased risk of MRD positivity, leukemia relapse, and poorer survival outcomes
View Article and Find Full Text PDF

Background: Relapse was the major cause of treatment failure in patients with myeloid malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients who still suffer from the disease while cannot be detected by morphological analysis can be identified by the minimal residual disease (MRD) monitoring. The most used first-line regimens for MRD are immunotherapies.

View Article and Find Full Text PDF
Article Synopsis
  • Chemotherapy is an effective treatment for acute myeloid leukemia (AML) but often leads to myelosuppression and poor recovery of blood cell production.
  • Dysfunction in bone marrow endothelial cells (ECs) is observed in AML patients, particularly those with inadequate hematopoietic reconstitution post-transplantation, making it essential to understand the mechanisms behind this dysfunction.
  • Elevated TGF-β signaling in ECs from AML patients causes damage that impairs hematopoiesis, but using TGF-β inhibitors has shown promise in restoring EC function and normal blood cell production without worsening AML.
View Article and Find Full Text PDF
Article Synopsis
  • RET fusions are linked to non-small cell lung cancer (NSCLC), and while RET-targeted treatments like Prasetinib have been effective, patients can develop resistance, limiting their options.
  • A case study highlights a patient with advanced lung adenocarcinoma and RET fusion who initially responded well to Prasetinib but later faced malignant pleural effusion after 24 months.
  • The patient received a combination of intrapleural and systemic Tislelizumab injections with chemotherapy, leading to significant clinical improvement and control of pleural effusion for over six months, suggesting intrapleural immunotherapy as a promising option for treatment-resistant cases.
View Article and Find Full Text PDF
Article Synopsis
  • This study looked at different treatments for patients with blood cancers who had a transplant, comparing two specific methods: PTCy alone and PTCy with a lower dose of ATG.
  • Researchers matched patients from these groups to ensure the comparisons were fair and accurate.
  • Results showed that the PTCy group had better outcomes, including quicker recovery of important blood cells called neutrophils and platelets, which are crucial for fighting infections and clotting.
View Article and Find Full Text PDF

Measurable residual disease (MRD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an independent risk factor for relapse in patients with acute lymphoblastic leukemia (ALL). This study aimed to assess the efficacy, safety, and immune reconstitution of chimeric antigen receptor T-cell (CAR-T) therapy in patients with molecular relapse after allo-HSCT. Eleven patients with molecular relapse of B-cell-ALL who underwent CAR-T therapy after allo-HSCT were enrolled.

View Article and Find Full Text PDF
Article Synopsis
  • A phase II trial was conducted to test the efficacy of a high-dose decitabine treatment (MegaDAC) for patients with relapsed/refractory acute myeloid leukemia (R/R AML) who did not respond to other targeted therapies, enrolling 70 patients from 2019 to 2023.
  • Despite previous treatments, all patients who underwent MegaDAC after allogeneic hematopoietic cell transplantation (allo-HCT) achieved minimal residual disease (MRD) negativity, showing a significant reduction in genetic abnormalities without major toxicity.
  • The results indicate promising long-term outcomes for patients, with a 2-year cumulative incidence of relapse of 29.6% and overall survival rate of 58.6%, suggesting
View Article and Find Full Text PDF
Article Synopsis
  • In 2018, the Chinese Society of Haematology established guidelines for monitoring and treating leukaemia relapse after stem cell transplantation, enhancing China's clinical practices and global integration.
  • Recently, experts updated the consensus to include a strategy focused on measurable residual disease (MRD) and improved therapies, emphasizing haploidentical HSCT for high-risk patients.
  • The updated guidelines promote advancements in MRD detection methods and explore new targeted treatment options, underscoring a significant progression in managing post-transplant leukaemia relapses.
View Article and Find Full Text PDF
Article Synopsis
  • - The study focused on analyzing changes in lysine-specific methyltransferase 2A partial tandem duplications (-PTD) in AML patients before and after receiving haploidentical donor hematopoietic stem cell transplantation (HID HSCT).
  • - Among 64 AML patients, those with pre-HSCT -PTD levels ≥1% experienced a slower decrease in -PTD levels post-transplant and had a significantly higher risk of relapse at 2 years compared to those with levels <1%.
  • - Pre-transplant -PTD levels ≥1% were identified as an independent risk factor for relapse, highlighting its potential as a predictive marker for patient outcomes following HID HSCT.
View Article and Find Full Text PDF
Article Synopsis
  • In the last two years, 39,918 hematopoietic stem cell transplantation (HSCT) cases were reported, with 18,194 in 2022 and 21,714 in 2023, showing an increase in procedures.
  • Autologous HSCT made up 31% (6562 cases) in 2022, while allogeneic HSCT accounted for 69% (12,632 cases), with allogeneic continuing to dominate in 2023.
  • Acute leukemia was the most common reason for HSCT, with acute myeloid leukemia (AML) as the top condition; the primary source of stem cells was peripheral blood, and a BuCy-based conditioning regimen was most widely
View Article and Find Full Text PDF
Article Synopsis
  • Wild giant pandas are naturally solitary, but captivity can change their social dynamics; this study explores how group housing affects their behavior and physiology.
  • Six captive giant pandas were divided into two groups post-breeding to assess differences in behavior, physiology, and gut bacteria.
  • Results showed that group-housed pandas engaged in more play and less stereotyped behavior, while gut microbiota diversity increased; overall, group living appeared less stressful for the pandas.
View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) was driven by the interplay between modifiable environmental factors and β-amyloid (Aβ) pathology. We aimed to investigate the interaction effects of mild depressive symptoms (MDS) with Aβ on AD development.

Methods: Longitudinal data of 1746 non-demented adults (mean age = 73 years, female = 53 %, maximum = 10 years) were derived from the Alzheimer's Disease Neuroimaging Initiative cohort.

View Article and Find Full Text PDF
Article Synopsis
  • The incidence of herpes zoster (HZ) is notably higher in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT) compared to the general population, prompting a recommendation for antiviral prophylaxis.
  • A retrospective study identified 201 patients who developed late-onset HZ (diagnosed over a year after transplantation) at Peking University People's Hospital, revealing key risk factors such as age over 20, lack of neutrophil engraftment within 14 days, and certain immune cell ratios.
  • A new stratification algorithm was created to classify transplant recipients into three risk categories based on these predictors, highlighting the need for further validation to improve antiviral prophylaxis post-transplantation.
View Article and Find Full Text PDF